Top

Published in:

01-10-2024 | Cytostatic Therapy | Review Article

The Sirt1/Nrf2 pathway is a key factor for drug therapy in chemotherapy-induced cardiotoxicity: a Mini-Review

Authors: Suleiman Ibrahim Shelash Mohammad, Asokan Vasudevan, Felix Oghenemaro Enwa, Jaya Bansal, Mamata Chahar, Mamdouh Eldesoqui, Muhammad Ikram Ullah, Zhanna R. Gardanova, Hanen Mahmod Hulail, Ahmed Hussein Zwamel

Published in: Medical Oncology | Issue 10/2024

Abstract

The likelihood of survival for cancer patients has greatly improved due to chemotherapy medicines. However, these antitumor agents might also have unfavorable effects on the cardiovascular system, which could result in sudden or gradual cardiac failure. The production of free radicals that result in oxidative stress appears to be the key mechanism by which chemotherapy-induced cardiotoxicity (CIC) happens. Reports suggest that the Sirtuin-1 (Sirt1)/Nuclear factor E2-associated factor 2 (Nrf2) signaling pathway has been considered an alternative path for counteracting cardiotoxicity by suppressing oxidative stress, inflammation, and apoptosis. This review concludes recent knowledge about CIC with a special focus on the anti-oxidative regulation properties of the Sirt1/Nrf2 pathway.

Bandyopadhyay D, et al. Oxidative stress-induced ischemic heart disease: protection by antioxidants. Curr Med Chem. 2004;11(3):369–87. https://doi.org/10.2174/0929867043456016.CrossRefPubMed

Curigliano G, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66(4):309–25. https://doi.org/10.3322/caac.21341.CrossRefPubMed

de Moor JS, et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013;22(4):561–70. https://doi.org/10.1158/1055-9965.EPI-12-1356.CrossRefPubMedPubMedCentral

Falzone L, Salomone S, Libra M. Evolution of cancer pharmacological Treatments at the turn of the third millennium. Front Pharmacol. 2018;9:1300. https://doi.org/10.3389/fphar.2018.01300.CrossRefPubMedPubMedCentral

Madmoli M. Engineering and technology, evaluation of chemotherapy complications in patients with cancer: a systematic review. Int J Res Stud Sci Eng Technol. 2018;5(12):59–64.

DeVita VT Jr, Chu EJCR. A history of cancer chemotherapy. Cancer Res. 2008;68:8643.CrossRefPubMed

Lu G, et al. Resveratrol and FGF1 synergistically ameliorates doxorubicin-induced cardiotoxicity via activation of SIRT1-NRF2 pathway. Nutrients. 2022. https://doi.org/10.3390/nu14194017.CrossRefPubMedPubMedCentral

Bhagat A, Kleinerman ES. Anthracycline-induced cardiotoxicity: causes, mechanisms, and prevention. Adv Exp Med Biol. 2020;1257:181–92. https://doi.org/10.1007/978-3-030-43032-0_15.CrossRefPubMed

Liu P, et al. Hesperetin modulates the Sirt1/Nrf2 signaling pathway in counteracting myocardial ischemia through suppression of oxidative stress, inflammation, and apoptosis. Biomed Pharmacother. 2021;139:111552. https://doi.org/10.1016/j.biopha.2021.111552.CrossRefPubMed

10.

Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34(15):1102–11. https://doi.org/10.1093/eurheartj/ehs181.CrossRefPubMed

11.

Ewer MS, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820–6. https://doi.org/10.1200/JCO.2005.13.300.CrossRefPubMed

12.

Gianni L, et al. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol. 2008;26(22):3777–84. https://doi.org/10.1200/JCO.2007.14.9401.CrossRefPubMed

13.

Smith LA, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337. https://doi.org/10.1186/1471-2407-10-337.CrossRefPubMedPubMedCentral

14.

Cardinale D, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002;13(5):710–5. https://doi.org/10.1093/annonc/mdf170.CrossRefPubMed

15.

Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111(21):2837–49. https://doi.org/10.1161/CIRCULATIONAHA.104.500546.CrossRefPubMed

16.

Soignet SL, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19(18):3852–60. https://doi.org/10.1200/JCO.2001.19.18.3852.CrossRefPubMed

17.

Subbiah V, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021;9(8):491–501. https://doi.org/10.1016/S2213-8587(21)00120-0.CrossRefPubMed

18.

Kantarjian HM, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841–51. https://doi.org/10.1038/leu.2012.134.CrossRefPubMed

19.

Moore RA, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29(25):3466–73. https://doi.org/10.1200/JCO.2011.35.5669.CrossRefPubMedPubMedCentral

20.

Nalluri SR, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277–85. https://doi.org/10.1001/jama.2008.656.CrossRefPubMed

21.

Miller K, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–76. https://doi.org/10.1056/NEJMoa072113.CrossRefPubMed

22.

Choueiri TK, et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010;28(13):2280–5. https://doi.org/10.1200/JCO.2009.27.2757.CrossRefPubMed

23.

Di Lorenzo G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009;20(9):1535–42. https://doi.org/10.1093/annonc/mdp025.CrossRefPubMed

24.

Richards CJ, et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol. 2011;29(25):3450–6. https://doi.org/10.1200/JCO.2010.34.4309.CrossRefPubMed

25.

Kerkelä R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908–16. https://doi.org/10.1038/nm1446.CrossRefPubMed

26.

Atallah E, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110(4):1233–7. https://doi.org/10.1182/blood-2007-01-070144.CrossRefPubMed

27.

Wu S, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9(2):117–23. https://doi.org/10.1016/S1470-2045(08)70003-2.CrossRefPubMed

28.

Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009;48(1):9–17. https://doi.org/10.1080/02841860802314720.CrossRefPubMed

29.

Chang HC, Guarente L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab. 2014;25(3):138–45. https://doi.org/10.1016/j.tem.2013.12.001.CrossRefPubMed

30.

Hu C, et al. Meteorin-like protein attenuates doxorubicin-induced cardiotoxicity via activating cAMP/PKA/SIRT1 pathway. Redox Biol. 2020;37:101747. https://doi.org/10.1016/j.redox.2020.101747.CrossRefPubMedPubMedCentral

31.

Saha S, et al. An overview of Nrf2 signaling pathway and its role in inflammation. Molecules. 2020. https://doi.org/10.3390/molecules25225474.CrossRefPubMedPubMedCentral

32.

Wang AJ, et al. Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways. Cell Mol Life Sci. 2021;78(7):3105–25. https://doi.org/10.1007/s00018-020-03729-y.CrossRefPubMedPubMedCentral

33.

Shen Y, et al. Involvement of Nrf2 in myocardial ischemia and reperfusion injury. Int J Biol Macromol. 2019;125:496–502. https://doi.org/10.1016/j.ijbiomac.2018.11.190.CrossRefPubMed

34.

Christidi E, Brunham LR. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2021;12(4):339. https://doi.org/10.1038/s41419-021-03614-x.CrossRefPubMedPubMedCentral

35.

Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104(12):971–7. https://doi.org/10.1136/heartjnl-2017-312103.CrossRefPubMed

36.

Kerins MJ, Ooi A. The roles of NRF2 in modulating cellular iron homeostasis. Antioxid Redox Signal. 2018;29(17):1756–73. https://doi.org/10.1089/ars.2017.7176.CrossRefPubMedPubMedCentral

37.

Gu J, et al. Pinocembrin inhibited cardiomyocyte pyroptosis against doxorubicin-induced cardiac dysfunction via regulating Nrf2/Sirt3 signaling pathway. Int Immunopharmacol. 2021;95:107533. https://doi.org/10.1016/j.intimp.2021.107533.CrossRefPubMed

38.

Zhang W, et al. Network pharmacology for systematic understanding of schisandrin B reduces the epithelial cells injury of colitis through regulating pyroptosis by AMPK/Nrf2/NLRP3 inflammasome. Aging. 2021;13:23193.CrossRefPubMedPubMedCentral

39.

Liou CJ, et al. Fisetin protects against hepatic steatosis through regulation of the Sirt1/AMPK and fatty acid β-oxidation signaling pathway in high-fat diet-induced obese mice. Cell Physiol Biochem. 2018;49(5):1870–84. https://doi.org/10.1159/000493650.CrossRefPubMed

Title: The Sirt1/Nrf2 pathway is a key factor for drug therapy in chemotherapy-induced cardiotoxicity: a Mini-Review
Authors: Suleiman Ibrahim Shelash Mohammad
Asokan Vasudevan
Felix Oghenemaro Enwa
Jaya Bansal
Mamata Chahar
Mamdouh Eldesoqui
Muhammad Ikram Ullah
Zhanna R. Gardanova
Hanen Mahmod Hulail
Ahmed Hussein Zwamel
Publication date: 01-10-2024
Publisher: Springer US
Keywords: Cytostatic Therapy
Anthracycline
Heart Failure
Sunitinib
Sorafenib
Published in: Medical Oncology / Issue 10/2024
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-024-02494-3

2024 ESC Congress

Noise pollution dangerous for heart health

02-09-2024
Myocardial Infarction
News

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Antihypertensives: more effective at morning or night?

02-09-2024
Hypertension
News

Low Lp(a) levels unlikely to increase the risk of diabetes

02-09-2024
Type 2 Diabetes
News

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

The Sirt1/Nrf2 pathway is a key factor for drug therapy in chemotherapy-induced cardiotoxicity: a Mini-Review

Abstract

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2024

How mitochondrial dynamics imbalance affects the progression of breast cancer:a mini review

Advances in immunotoxin engineering: precision therapeutic strategies in modern oncology

Lipid metabolism reprogramming in renal cell carcinomas

Turning the tide: pembrolizumab’s triumph in adjuvant RCC therapy

Letter to the editor: comment on “Chitosan-loaded piperlongumine nanoparticles and kaempferol enhance the anti-cancer action of doxorubicin in targeting of Ehrlich solid adenocarcinoma: in vivo and in silico modeling study”

Incidence of lymphedema related to various cancers

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials